Avantor, Inc. (AVTR)

Insider Trading Filed: 2026-05-11

Key Insights

Director Murthy Mala acquired 25,270 restricted stock units (RSUs) on 05/07/2026 at no cost, vesting one year later on 05/07/2027, representing standard equity compensation rather than open market purchases.
The filing shows Mala's total beneficial ownership increased to 69,479 shares following this grant, indicating a meaningful stake in the company aligned with director responsibilities.
This is a routine equity grant to a board member with no sale or disposition activity, suggesting stable insider confidence without profit-taking or concern-driven transactions.
The use of an attorney-in-fact to sign the filing is standard administrative procedure and does not indicate any unusual circumstances or conflicts of interest.

Insider Trading Filed: 2026-05-11

Key Insights

Director Gregory T. Lucier acquired 25,270 restricted stock units (RSUs) on 05/07/2026 at no cost with a one-year vesting schedule, indicating company confidence in future performance and aligning executive interests with shareholders.
Lucier made a separate open market purchase of 10,000 shares at an average price of $8.32 on 05/08/2026, demonstrating personal conviction in the stock and suggesting insider confidence at current valuation levels.
Total beneficial ownership increased to 94,006 shares (34,006 direct + 60,000 indirect via trust), with the trust-based indirect holding representing a significant portion of total position and indicating long-term wealth accumulation strategy.

Insider Trading Filed: 2026-05-11

Key Insights

Director Simon Dingemans acquired 25,270 shares of common stock on 05/07/2026 at $0 price, indicating a restricted stock unit (RSU) grant rather than an open market purchase.
The RSU grant vests on May 7, 2027, representing a one-year vesting schedule typical for director compensation at this company.
Following this transaction, Dingemans beneficially owns 31,495 shares directly, suggesting modest accumulation of equity ownership aligned with director incentive structures.
The filing was executed by Scott Baker as Attorney-in-Fact and filed on 05/11/2026, four business days after the transaction date, indicating timely SEC compliance.

Insider Trading Filed: 2026-05-11

Key Insights

Director Louise Makin acquired 25,270 restricted stock units (RSUs) on 05/07/2026 at no monetary cost, vesting on 05/07/2027, indicating this is a standard equity compensation grant rather than a discretionary buy signal.
The grant increases Makin's beneficial ownership to 47,140 shares following the transaction, showing meaningful accumulated equity stake in the company aligned with director interests.
The filing was signed by Scott Baker as Attorney-in-Fact on 05/11/2026, three business days after the transaction date, which is consistent with normal Form 4 filing timelines and suggests routine administrative processing.

Insider Trading Filed: 2026-05-11

Key Insights

Director Joseph R. Massaro acquired 25,270 shares of common stock through a restricted stock unit grant on May 7, 2026, vesting in one year, indicating continued executive compensation alignment with company performance.
The grant was issued at $0 price, reflecting standard RSU compensation rather than open market purchases, which is typical for director equity incentives but does not signal insider confidence in stock valuation.
Massaro's total beneficial ownership increased to 77,408 shares following this transaction, demonstrating meaningful direct equity stake in the company as a board member.
The transaction was executed through Scott Baker as attorney-in-fact and filed within the required four-business-day window, indicating proper compliance with SEC reporting requirements.

Insider Trading Filed: 2026-05-11

Key Insights

Director Sanjeev K Mehra acquired 25,270 restricted stock units (RSUs) on 05/07/2026 at $0 price, vesting on 05/07/2027, indicating equity compensation tied to one-year retention.
Mehra maintains indirect beneficial ownership of 475,000 shares through a limited liability company, with a disclaimer of beneficial ownership except for pecuniary interest, suggesting significant long-term stake in the company.
Total direct beneficial ownership following the transaction is 33,376 shares, representing a modest position relative to indirect holdings, which may indicate the indirect entity holds founder or prior investment stakes.
The filing shows routine director compensation activity with no material trading activity, suggesting confidence in the company's direction but no significant insider buying pressure at current valuations.

Insider Trading Filed: 2026-05-11

Key Insights

Director Michael Severino acquired 25,270 restricted stock units (RSUs) on 05/07/2026 at no cost, vesting on 05/07/2027, bringing his total beneficial ownership to 85,821 shares in direct form.
The grant of RSUs with a one-year vesting schedule represents standard equity compensation for board members and demonstrates confidence in the company's direction, though it does not indicate insider buying conviction.
This is a routine equity grant transaction typical of director compensation practices, with no material significance regarding stock valuation or company performance metrics.

Insider Trading Filed: 2026-05-11

Key Insights

Director Gregory L. Summe acquired 25,270 restricted stock units (RSUs) on 05/07/2026 at $0 exercise price, vesting on 05/07/2027, indicating continued equity compensation alignment with company performance.
Summe maintains significant beneficial ownership of 400,000 shares held indirectly through a trust, demonstrating substantial long-term stake in Avantor beyond direct holdings of 83,381 shares.
The grant of RSUs at zero cost is a standard equity compensation practice for directors and reflects confidence in the company's future prospects, though the vesting period of one year is typical for director compensation.

Quarterly Report Filed: 2026-04-29

Key Insights

The filing shows Avantor operates through two primary segments: Bioscience Medtech Products and VWR Distribution Services, with multiple debt instruments including senior notes and term loans maturing between 2024-2032, indicating a structured but leveraged capital structure.
The company has accumulated other comprehensive income adjustments and translation differences across quarters, suggesting exposure to foreign exchange volatility and potential hedging activities that impact reported earnings.
Environmental liabilities are disclosed for operations in New Jersey and Poland with minimum/maximum ranges noted, which could represent material contingent obligations requiring monitoring for potential financial impact.
The presence of capital lease obligations and multiple credit facilities (revolving credit amended to mature October 2030, term loans maturing October 2030 and 2032) indicates active management of working capital and debt refinancing needs in the near to medium term.

Current Report Filed: 2026-04-29

Key Insights

Avantor announced Q1 2026 financial results on April 29, 2026, indicating operational performance for the quarter ended March 31, 2026, though specific financial metrics are not disclosed in the 8-K body itself.
The filing is a standard earnings announcement with minimal material detail provided in the 8-K form, with the substantive financial information contained in the attached press release (Exhibit 99.1).
Signed by Steven Eck, Senior Vice President and Chief Accounting Officer, indicating normal financial reporting procedures with no executive or leadership changes evident from this filing.

Insider Trading Filed: 2026-04-06

Key Insights

Steven Eck, SVP and Chief Accounting Officer of Avantor, Inc., acquired 31,645 shares of the company's common stock through a grant of restricted stock units.
The restricted stock units vest in three equal annual installments starting on April 3, 2027, indicating Eck's long-term commitment to the company.
Insider buying, such as this acquisition, can be a positive signal for investors as it suggests management's confidence in the company's future performance.

Current Report Filed: 2026-04-01

Key Insights

Avantor's CFO, Mr. R. Brent Jones, has resigned to join a company outside the life sciences industry. This leadership change may introduce uncertainty in the near term.
The company has appointed Steven Eck, the current Senior Vice President and Chief Accounting Officer, as the interim CFO while it undertakes a search for a permanent replacement.
To compensate Mr. Eck for the additional responsibilities as interim CFO, the company has provided him with a monthly payment and a one-time restricted stock unit award, aligning his interests with shareholders.

Insider Trading Filed: 2026-02-25

Key Insights

Insider Claudius Sokenu, the EVP and Chief Legal & Compliance Officer, disposed of 2,376 shares of Avantor, Inc. (AVTR) common stock on February 23, 2026.
The shares were disposed of via a 'F' transaction, meaning they were withheld by the company to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
Following the transaction, Sokenu continues to beneficially own 252,429 shares of Avantor's common stock.

Insider Trading Filed: 2026-02-25

Key Insights

Brittany Hankamer, EVP and Chief HR Officer, sold 1,683 shares of Avantor, Inc. (AVTR) on February 23 and 24, 2026, likely for tax withholding purposes.
Hankamer's ownership decreased by 0.14% to 249,045 shares following the reported transactions.
The transactions appear routine and do not suggest any significant change in Hankamer's overall position or sentiment towards the company.

Insider Trading Filed: 2026-02-25

Key Insights

The reporting person, R. Brent Jones, who is the Executive Vice President and Chief Financial Officer of Avantor, Inc. (AVTR), disposed of 2,805 shares of the company's common stock on February 23, 2026.
The shares were disposed of through a 'F' transaction, which typically indicates the shares were withheld by the company to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs).
Following the transaction, the reporting person beneficially owns 419,782 shares of Avantor's common stock, representing their direct ownership in the company.

Insider Trading Filed: 2026-02-25

Key Insights

Benoit Gourdier, the EVP of Bioscience & Medtech at Avantor, Inc. (AVTR), disposed of 3,029 shares of common stock on February 23, 2026, through a tax withholding transaction.
Following the reported transaction, Gourdier still holds 362,859 shares of Avantor's common stock, indicating he maintains a significant ownership position in the company.
This insider transaction provides insight into Avantor's executive compensation and equity incentive programs, as well as Gourdier's ongoing commitment to the company.

Insider Trading Filed: 2026-02-25

Key Insights

The reporting person, Steven W. Eck, who is the SVP and Chief Accounting Officer of Avantor, Inc. (AVTR), has disposed of 2,469 shares of the company's common stock through share withholding to cover tax obligations.
The transactions occurred on February 23, 2026 and February 24, 2026, at prices of $8.89 and $9.11, respectively.
Following the reported transactions, the reporting person still holds 99,333 shares of Avantor's common stock, indicating continued ownership and commitment to the company.

Insider Trading Filed: 2026-02-12

Key Insights

Gregory L. Summe, a director of Avantor, Inc., has acquired an additional 100,000 shares of the company's common stock at $9.4 per share, increasing his beneficial ownership to 400,000 shares.
The reported transaction represents an increase in Summe's direct ownership of Avantor shares, potentially signaling his confidence in the company's future performance.
Insider buying activity, especially by a director, can be seen as a positive signal to investors, as it suggests the insider believes the stock is undervalued and has potential for future growth.

Current Report Filed: 2026-02-11

Key Insights

Avantor, Inc. announced a realignment of its reportable business segments, consolidating into two new segments: VWR Distribution & Services and Bioscience & Medtech Products, effective in Q1 2026.
The company provided unaudited supplemental recast financial information for fiscal years 2023-2025 to assist investors in understanding the effects of the segment reporting changes on its historical results.
Avantor reported its Q4 2025 and full-year 2025 financial results, which will be discussed on a conference call with investors on February 11, 2026.

Annual Report Filed: 2026-02-11

Key Insights

Avantor's revenue and profitability have grown steadily over the past 3 years, indicating strong operational performance.
The company has made strategic investments in its Laboratory Solutions and Bioscience Production segments, which account for the majority of its revenue and growth.
Avantor faces potential risks from customer concentration, unionized employee concentration, and rising costs of materials and services, which could impact its future financial results.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information